Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
1.660
-0.160 (-8.79%)
Nov 20, 2026, 4:00 PM EST - Market closed
Longeveron Revenue
Longeveron had revenue of $115.00K in the quarter ending September 30, 2026, a decrease of -16.06%. This brings the company's total for the last twelve months to $1.17M, down -18.93% year-over-year. In the year 2025, Longeveron had annual revenue of $1.20M, down -49.87%. That makes Longeveron the 43,389th largest company in the world by revenue and 6,034th in the United States.
Revenue (ttm)
$1.17M
Revenue Growth
-18.93%
P/S Ratio
4.81
Revenue / Employee
$30,658
Employees
38
Market Cap
5.60M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | -1.19M | -49.87% |
| Dec 31, 2024 | 2.39M | 1.68M | 237.38% |
| Dec 31, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
LGVN News
- 8 days ago - Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - Longeveron Quarterly report: Q3 2026 - Filings
- 8 days ago - Longeveron Earnings release: Q3 2026 - Filings
- 24 days ago - Longeveron Announces Engagement of Lucid Capital Markets - GlobeNewsWire
- 26 days ago - Longeveron reports ELPIS II trial misses primary endpoint - TheFly
- 26 days ago - Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) - GlobeNewsWire
- 7 weeks ago - Longeveron to Participate in Three Longevity/Aging Investment Conferences - GlobeNewsWire
- 2 months ago - Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial - TipRanks